What’s Better Than Semaglutide for Weight Loss?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide transformed weight loss treatment when it became widely available, helping patients lose 5–15% of body weight in clinical trials. However, recent research shows that combination therapies and genetically informed protocols can produce superior outcomes for certain individuals. PlexusDx specializes in matching you to the right GLP-1 therapy—whether that's semaglutide alone or a more advanced option—based on your metabolic profile.

When Semaglutide Works Best for Weight Loss

Semaglutide monotherapy excels in patients with primary appetite dysregulation and moderate insulin resistance. The medication stimulates GLP-1 receptors in the brain and pancreas, reducing hunger signals and improving blood sugar control simultaneously. Compounded semaglutide injection from licensed 503A pharmacies delivers consistent results at a starting price of $189 per month, making it accessible without insurance or membership fees.

Clinical data shows semaglutide produces average weight loss of 10–15% over 68 weeks in non-diabetic populations. Response is fastest in patients under 50 with a BMI above 30 and no significant metabolic complications. However, a meaningful subset of users plateau after 6–12 months or experience side effects that limit dose escalation.

Dual-Agent Therapies: Beyond Single GLP-1 Medications

Tirzepatide—a GIP/GLP-1 receptor agonist—activates two distinct peptide pathways instead of one, producing weight loss of 20–22% in recent trials. This dual mechanism appeals to patients whose GIPR genetic variants show equal pathway sensitivity. PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan, plus the GLP-Squared Injection (semaglutide + tirzepatide combination) at $289/mo (or $249/mo on the 3-month plan) for those who benefit from sequential or simultaneous dual-agent dosing.

Combination protocols like GLP-Squared address treatment resistance by engaging multiple appetite and metabolic targets. Patients who stall on semaglutide alone often see renewed weight loss when a second agent is introduced. The strategy requires careful monitoring but can unlock an additional 5–10% weight reduction in responders.

The Role of Genetic Testing in Choosing Your Best Option

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Oral vs. Injectable GLP-1: Convenience and Effectiveness Trade-offs

Oral semaglutide ($289 per month) and oral tirzepatide ($349 per month) eliminate needle anxiety and fit discreetly into daily routines. Oral formulations require fasting and careful timing but deliver efficacy within 5–10% of injectable versions in most patients. PlexusDx offers both modalities through licensed 503A compounding pharmacies, ensuring quality and potency regardless of format.

Injectable versions typically show 10–15% higher peak concentrations and more consistent pharmacokinetics due to direct subcutaneous absorption. Injection patients often reach steady state faster and experience fewer gastric side effects. The choice between oral and injectable should align with your lifestyle, needle tolerance, and baseline GI sensitivity—not cost, since PlexusDx maintains flat monthly pricing across all formats and tiers.

The Microdose GLP-1 Protocol: Starting Gentle and Going Slower

PlexusDx's Microdose GLP-1 Protocol ($129 per month) delivers ultra-low starting doses for patients who are sensitive to nausea, anxiety around injections, or have contraindications to standard dosing. Microdose therapy still engages the GLP-1 pathway but extends the titration window, allowing your body to adapt gradually over 12–16 weeks. This approach benefits older adults, those with significant metabolic dysfunction, and patients starting weight loss therapy for the first time.

Research shows microdose protocols reduce early dropout rates and improve long-term adherence by minimizing nausea and appetite loss during the first 4 weeks. While absolute weight loss may be 2–3% lower than standard dosing at equivalent time points, dropout-adjusted efficacy often exceeds that of standard-speed protocols. Microdose is not a compromise—it is a precision strategy for sustainable results in vulnerable populations.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide really better than semaglutide for weight loss?

Tirzepatide produces 20–22% weight loss versus semaglutide's 10–15% in head-to-head trials, but individual response varies. Your genetic profile—specifically GIPR variants—determines whether you will benefit more from dual-agent therapy. PlexusDx's Precision Peptide Genetic Test identifies your optimal medication before you commit to treatment.

What is the difference between PlexusDx semaglutide and brand-name Ozempic?

PlexusDx semaglutide comes from licensed 503A compounding pharmacies and costs $189 per month, while Ozempic requires insurance or cash pricing of $1,000+. Both contain the same active ingredient and work identically; the difference is source, cost, and access. PlexusDx serves all 50 states, accepts HSA/FSA funds, and requires no membership fees.

Can I switch from semaglutide to tirzepatide if I am not losing weight?

Yes, many patients transition from semaglutide monotherapy to tirzepatide or GLP-Squared combination therapy if they plateau after 8–12 weeks. PlexusDx supports protocol changes at no additional cost; your monthly rate remains flat across all medication tiers. A brief clinical conversation with your PlexusDx provider will determine the safest switch strategy.

Are compounded GLP-1 medications as safe as FDA-approved versions?

Compounded medications from licensed 503A pharmacies meet strict quality, sterility, and potency standards enforced by state boards of pharmacy and the DEA. They are not FDA-approved as finished products, but 503A compounds are legal, regulated, and pharmacologically identical to brand-name counterparts. PlexusDx partners exclusively with 503A facilities—never 503B—ensuring pharmaceutical-grade safety.

What does the Precision Peptide Genetic Test actually tell me?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Semaglutide For Weight Loss 2
• Semaglutide Tablets For Weight Loss
• Semaglutide Pills For Weight Loss
• Oral Semaglutide Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.